<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-239</article-id><article-id pub-id-type="pmid">19615087</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-239</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Regulation of <italic>MYCN </italic>expression in human neuroblastoma cells</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Jacobs</surname><given-names>Joannes FM</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>H.Jacobs@abti.umcn.nl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>van Bokhoven</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>H.vanBokhoven@antrg.umcn.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>van Leeuwen</surname><given-names>Frank N</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>FN.vanLeeuwen@cukz.umcn.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Hulsbergen-van de Kaa</surname><given-names>Christina A</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>C.Hulsbergen@pathol.umcn.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>de Vries</surname><given-names>I Jolanda M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>J.deVries@ncmls.ru.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Adema</surname><given-names>Gosse J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>G.Adema@ncmls.ru.nl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Hoogerbrugge</surname><given-names>Peter M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>P.Hoogerbrugge@cukz.umcn.nl</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>de Brouwer</surname><given-names>Arjan PM</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>A.deBrouwer@antrg.umcn.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, the Netherlands</aff><aff id="I2"><label>2</label>Department of Pediatric Hemato-Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands</aff><aff id="I3"><label>3</label>Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Donders Institute for Brain, Cognition and Behaviour, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands</aff><aff id="I4"><label>4</label>Department of Bloodtransfusion and Transplantation Immunology, University Nijmegen Medical Centre, Nijmegen, the Netherlands</aff><aff id="I5"><label>5</label>Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2009</year></pub-date><volume>9</volume><fpage>239</fpage><lpage>239</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/239"/><history><date date-type="received"><day>8</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Jacobs et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Jacobs et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Jacobs FM Joannes H.Jacobs@abti.umcn.nl </dc:author><dc:title> Regulation of MYCN expression in human neuroblastoma cells </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 239-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;239&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Amplification of the <italic>MYCN </italic>gene in neuroblastoma (NB) is associated with a poor prognosis. However, <italic>MYCN</italic>-amplification does not automatically result in higher expression of <italic>MYCN </italic>in children with NB. We hypothesized that the discrepancy between <italic>MYCN </italic>gene expression and prognosis in these children might be explained by the expression of either MYCN-opposite strand (<italic>MYCNOS</italic>) or the shortened MYCN-isoform (<italic>&#x00394;MYCN</italic>) that was recently identified in fetal tissues. Both <italic>MYCNOS </italic>and &#x00394;MYCN are potential inhibitors of MYCN either at the mRNA or at the protein level.</p></sec><sec sec-type="methods"><title>Methods</title><p>Expression of <italic>MYCN, MYCNOS </italic>and <italic>&#x00394;MYCN </italic>was measured in human NB tissues of different stages. Transcript levels were quantified using a real-time reverse transcriptase polymerase chain reaction assay (QPCR). In addition, relative expression of these three transcripts was compared to the number of <italic>MYCN </italic>copies, which was determined by genomic real-time PCR (gQPCR).</p></sec><sec><title>Results</title><p>Both <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>are expressed in all NBs examined. In NBs with <italic>MYCN</italic>-amplification, these transcripts are significantly higher expressed. The ratio of <italic>MYCN:&#x00394;MYCN </italic>expression was identical in all tested NBs. This indicates that <italic>&#x00394;MYCN </italic>and <italic>MYCN </italic>are co-regulated, which suggests that &#x00394;MYCN is not a regulator of MYCN in NB. However, the ratio of <italic>MYCNOS:MYCN </italic>expression is directly correlated with NB disease stage (<italic>p </italic>= 0.007). In the more advanced NB stages and NBs with <italic>MYCN</italic>-amplification, relatively more <italic>MYCNOS </italic>is present as compared to <italic>MYCN</italic>. Expression of the antisense gene <italic>MYCNOS </italic>might be relevant to the progression of NB, potentially by directly inhibiting <italic>MYCN </italic>transcription by transcriptional interference at the DNA level.</p></sec><sec><title>Conclusion</title><p>The <italic>MYCNOS:MYCN</italic>-ratio in NBs is significantly correlated with both <italic>MYCN</italic>-amplification and NB-stage. Our data indicate that in NB, MYCN expression levels might be influenced by <italic>MYCNOS </italic>but not by &#x00394;MYCN.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Neuroblastoma cells (NBs) that carry an amplified <italic>MYCN </italic>gene are extremely malignant. However, <italic>MYCN-</italic>amplification does not automatically result in higher expression of <italic>MYCN </italic>in children with NB [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Thus, it has been suggested that the aggressive phenotype of <italic>MYCN </italic>amplified NBs may be explained by higher expression levels of other genes co-amplified with <italic>MYCN</italic>, since the amplified unit of DNA can be up to 1 Mb. To date, three genes have been identified that are frequently co-amplified with <italic>MYCN </italic>in NBs: <italic>DDX1 </italic>in 50% of the cases, <italic>NAG </italic>in 20% of the tumours, and <italic>MYCNOS </italic>in all cases [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. All three genes demonstrate increased transcript expression when co-amplified in NB cell lines, indicating that they may contribute to tumour phenotype. However, survival analyses in a large study using 75 <italic>MYCN</italic>-amplified tumours indicate that neither amplified <italic>DDX1 </italic>nor <italic>NAG </italic>have an additional adverse effect on the prognosis of the patients [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Natural antisense transcripts are abundant in eukaryotic genomes [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. In human, more than 1600 natural antisense transcript are predicted to be present [<xref ref-type="bibr" rid="B10">10</xref>]. They can influence gene expression on the DNA level by transcriptional interference, on the transcript level by RNA interference and RNA editing, or direct splicing by RNA masking [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. <italic>MYCNOS </italic>is the antisense transcript of <italic>MYCN </italic>[<xref ref-type="bibr" rid="B13">13</xref>] and shows overlap with the first exon of <italic>MYCN</italic>. This antisense transcript could be involved in modulating the expression of <italic>MYCN </italic>by any of the mechanisms mentioned above. Antisense transcripts are considered to be relevant to the development and progression of tumours [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>], but until now, only antisense <italic>HIF-1&#x003b1; </italic>RNA has been shown to be a marker for prognosis in human breast cancer [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Recently, we reported a fetal MYCN splice variant (<italic>&#x00394;MYCN</italic>) lacking exon 2 [<xref ref-type="bibr" rid="B18">18</xref>]. The <italic>&#x00394;MYCN </italic>transcript is expressed in several fetal tissues and contains the acidic region, nuclear localization signal, the basic helix-loop-helix and leucine-zipper domains but lacks the transactivation domain. It has been suggested that the &#x00394;MYCN protein may serve as an obligate dimerization partner for MYCN to convey transcriptional activation or repression.</p><p>In this report we analysed whether expression of <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>influence <italic>MYCN </italic>expression levels in NBs of different disease stages.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Tumour material</title><p>Sixteen fresh-frozen NBs were obtained from at the Department of Pathology at the Radboud University Nijmegen Medical Centre. All NBs were derived from pediatric patients (0 to 6-years-old) diagnosed at the Department of Pediatric Hemato-Oncology. Sections of the frozen samples were stained with hematoxylin-eosin and reviewed by the pathologist to verify tumour histology and to evaluate the percentage of tumour cells. Samples were only considered for study if the contents of tumour cells was &#x02265; 75%. Six out of 16 NBs had <italic>MYCN</italic>-amplification as shown by southern blot and/or fluorescent in situ hybridization (FISH). All samples were anonymized prior to this study, and the research program was approved by the local ethics committee (Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen).</p></sec><sec><title>DNA isolation, RNA isolation and cDNA synthesis</title><p>Tumour samples were aliquoted in two parts to isolate both DNA and RNA. Total DNA was isolated with the QIAamp isolation-kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. All samples were RNAse treated. Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA, USA) and treated with Deoxyribonuclease I (Dnase I; Invitrogen). DNase-treated RNA was reverse-transcribed using oligo(dT) primers with the SuperScript First-Strand Synthesis System (Invitrogen).</p></sec><sec><title>PCR</title><p><italic>MYCN </italic>and splice variants were amplified from cDNA by using the GC-RICH PCR System (Roche Applied Science, Almere, The Netherlands). Primers were developed by the primer3 program (<ext-link ext-link-type="uri" xlink:href="http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi"/>[<xref ref-type="bibr" rid="B19">19</xref>]). Primer sequences are shown in table <xref ref-type="table" rid="T1">1</xref> and the position of the primers in <italic>MYCN </italic>are depicted in figure <xref ref-type="fig" rid="F1">1</xref>. PCR products were sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction Kit and analysed with the ABI PRISM 3730 DNA analyser (Applied Biosystems, Foster City, CA, USA).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Schematic overview of (A) genomic organization, (B) transcripts, and (C) protein isoforms of <italic>MYCN </italic>and <italic>MYCNOS</italic></bold>. The localization of primer sites (small arrows) and the C-19 antibody epitope are indicated. (D) RT-PCR with primers on exon 1 and 3 on NB cDNA of patient 13 and NB cell line IMR-32 give products of 1007 bp (<italic>MYCN</italic>) and 100 bp (<italic>&#x00394;MYCN</italic>). The identity of both products was verified by sequence analysis.</p></caption><graphic xlink:href="1471-2407-9-239-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Primer-sequences of primers used in this report.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene of interest</bold></td><td align="left"><bold>Genbank ID</bold></td><td align="center"><bold>Forward primer</bold></td><td align="center"><bold>Reverse primer</bold></td></tr></thead><tbody><tr><td align="left"><bold>QPCR</bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><italic>MYCN</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-cacaaggccctcagtacctc-3'</td><td align="center">5'-accacgtcgatttcttcctc-3'</td></tr><tr><td align="left"><italic>&#x00394;MYCN</italic></td><td align="left">Not present</td><td align="center">5'-cagaatcgcctccggatc-3'</td><td align="center">5'-cgcttctccacagtgacca-3'</td></tr><tr><td align="left">MYCNOS</td><td align="left"><ext-link ext-link-type="gen" xlink:href="S49953.1">S49953.1</ext-link></td><td align="center">5'-tccgacagctcaaacacagac-3'</td><td align="center">5'-ccagctttgcagccttctc-3'</td></tr><tr><td align="left"><italic>MYCN </italic>total</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-cataaggggtttgccatttg-3'</td><td align="center">5'-ctaatactggccgcaaaagc-3'</td></tr><tr><td align="left"><italic>GUSB</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_000181.1">NM_000181.1</ext-link></td><td align="center">5'-agagtggtgctgaggattgg-3'</td><td align="center">5'-ccctcatgctctagcgtgtc-3'</td></tr><tr><td align="left"><italic>TFRC</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_003234.1">NM_003234.1</ext-link></td><td align="center">5'-gttcttctgtgtggcagttcag-3'</td><td align="center">5'-caggctgaaccgggtatatg-3'</td></tr><tr><td align="left"><italic>RNFIII</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_017610.6">NM_017610.6</ext-link></td><td align="center">5'-gcagaatgcagcagaagttg-3'</td><td align="center">5'-ccattcttgcagaagtggttg-3'</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>gQPCR</bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><italic>MYCN </italic>(exon 1)</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-ccgggtgtgtcagatttttc-3'</td><td align="center">5'-tccaacacagttcccaggag-3'</td></tr><tr><td align="left"><italic>MYCN </italic>(exon 2)</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-gatctgcaagaacccagacc-3'</td><td align="center">5'-ccgccgaagtagaagtcatc-3'</td></tr><tr><td align="left"><italic>MYCN </italic>(exon 3)</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-gttcctcctccaacaccaag-3'</td><td align="center">5'-aggcatcgtttgaggatcag-3'</td></tr><tr><td align="left"><italic>MYCN </italic>(3'-UTR)</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_005378.4">NM_005378.4</ext-link></td><td align="center">5'-taccaggtgcaggagagacc-3'</td><td align="center">5'-agcccaagtagccaagacac-3'</td></tr><tr><td align="left"><italic>MYCNOS</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="S49953.1">S49953.1</ext-link></td><td align="center">5'-aagaagggtagtccgaaggtg-3'</td><td align="center">5'-gaaactggaaacatccagagg-3'</td></tr><tr><td align="left"><italic>CFTR</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_000492.3">NM_000492.3</ext-link></td><td align="center">5'-gggtcttgataaatggcttcc-3'</td><td align="center">5'-tctggcttgcaaaacacaag-3'</td></tr><tr><td align="left"><italic>TBX22</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_016954.2">NM_016954.2</ext-link></td><td align="center">5'-tttaccggctcctgaaagac-3'</td><td align="center">5'-aaccgctttttgaattggtg-3'</td></tr><tr><td align="left"><italic>SLC16A2</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_006517.2">NM_006517.2</ext-link></td><td align="center">5'-cttcttcgtccctctgatgc-3'</td><td align="center">5'-tcaggggccaacatcttatc-3'</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="center"><italic>Cloning</italic></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><italic>MYCNOS</italic></td><td align="left"><ext-link ext-link-type="gen" xlink:href="S49953.1">S49953.1</ext-link></td><td align="center">5'-agggggtggtggcgaggc-3'</td><td align="center">5'-gtagctcgcacttatttatttat-3'</td></tr></tbody></table></table-wrap></sec><sec><title>QPCR and gQPCR</title><p>QPCR and gQPCR was performed by SYBR Green-based quantification (Bio-Rad, Veenendaal, The Netherlands). PCRs were performed on an iCycler (MyiQ single color Real-Time detection System, Bio-Rad, Veenendaal, The Netherlands). Sequences of the primers used to quantify cDNA transcript levels and genomic DNA are shown in table <xref ref-type="table" rid="T1">1</xref> and the position of the primers is depicted in figure <xref ref-type="fig" rid="F1">1</xref>. PCR products were between 80- and 100-bp. Validation of the primer pairs and (g)QPCR experiments were performed as described previously [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Differences in expression of a gene of interest or in genomic DNA copy number between two samples were calculated by the comparative Ct or 2<sup>&#x00394;&#x00394;Ct </sup>method [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Hoebeeck et al. described and validated a similar assay for the determination of MYCN copy numbers in tumor samples [<xref ref-type="bibr" rid="B24">24</xref>].</p></sec><sec><title>Antibody coupling and immunoprecipitation</title><p>NB-samples were homogenized in RIPA-buffer (50 mM Tris-HCl pH 7.4, 0.2% sodium dodecyl sulfate (SDS), 0.2% sodium deoxycholate, 1% triton X-100, 1 mM EDTA) supplemented with 1 mM DTT, 1 mM PMSF, aprotinin 2 &#x003bc;g/ml and leupeptin 2 &#x003bc;g/ml. Total protein concentration was determined according to the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA).</p><p>For immunoprecipitation, 5 &#x003bc;g C-19 mAb (Santa Cruz Biotechnology, Heidelberg, Germany) was coupled to Prot A sepharose CL-4B beads (Pharmacia Biotechnologies, Uppsala, Sweden) for 1 hour at 4&#x000b0;C to). NB-lysates were precleared O/N with 50 &#x003bc;l packed Prot A sepharose CL-4B beads. To the precleared lysates, 20 &#x003bc;l C-19-coupled beads was added and incubated for 24 h at 4&#x000b0;C. Subsequently, the beads were washed with PBS and resuspended in SDS sample buffer and stored at -80&#x000b0;C until SDS-polyacrylamide gel electrophoresis (PAGE).</p></sec><sec><title>SDS-PAGE and Western blotting</title><p>Samples (30 &#x003bc;g homogenized NB-sample or 20 &#x003bc;l precipitation beads) were separated a 10% polyacrylamide gels and transferred to nitrocellulose (Hi-bond, Amersham Biosciences, Little Chalfont, UK). Ponceau S staining was used to confirm that equal amounts of protein were loaded in each lane (additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The nitrocellulose blot was blocked with 1% BSA in 20 mM Tris-HCl pH 7.4 and 0.1% Tween (Tris-buffered saline/Tween 20; TBS-T) for 1 h. The blot was washed for 5 min with TBS-T followed by incubation with the C-19 anti-MYCN antibody 1:200 diluted in TBS-T for 1 h at RT. After washing 3&#x000d7; with TBS-T, the blot was incubated with HRP-conjugated swine-anti-rabbit antibody (1:5000 diluted in TBS-T) for 1 h at RT. Subsequently, the blot was washed and incubated for 1 min with ECL substrate (Amersham Biosciences, Little Chalfont, UK) and exposed to film (Kodak, Rochester, NY, USA).</p></sec><sec><title>Overexpression of MYCNOS in the NB cell line IMR-32</title><p>Primers for the amplification of <italic>MYCNOS </italic>were developed by using the primer3 program (Table <xref ref-type="table" rid="T1">1</xref>). <italic>MYCNOS </italic>was amplified from DNA isolated from a healthy control using the GC RICH PCR System (Roche, Woerden, The Netherlands). Subsequently, <italic>MYCNOS </italic>was cloned into the Gateway donor vector pDONR-201 (Invitrogen). Using the Gateway cloning system, <italic>MYCNOS </italic>was subsequently subcloned into the pcDNA3 expression vector and integrity of the construct was validated by sequence analysis. IMR-32 NB cells at 50% confluence in a 25 cm<sup>2 </sup>flask were co-transfected with 8 &#x003bc;g pcDNA3-<italic>MYCNOS </italic>and C1-<italic>GFP </italic>using 120 &#x003bc;l lipofectamine (Invitrogen) in 3 ml Opti-MEM-I for 20 min at RT.</p></sec><sec><title>Statistical analysis</title><p>Statistically significant differences in expression of <italic>MYCN</italic>-transcripts between NBs with or without <italic>MYCN</italic>-amplification were calculated with Students' T-test. Correlation of <italic>MYCN</italic>-transcipt expression with disease stage was calculated using the Spearman rank correlation and correlation of MYCN-transcripts with the <italic>MYCN</italic>-amplification numbers was calculated with the Pearson correlation test. All statistical tests were two-sided, significance was determined as p &#x0003c; 0.05.</p></sec></sec><sec><title>Results</title><sec><title>Patient characteristics</title><p>We analysed fresh-frozen NBs from 16 pediatric patients (age range: 0&#x02013;6 years old). The NBs are classified according to the Children's Cancer Group Neuroblastoma Staging System [<xref ref-type="bibr" rid="B25">25</xref>] and treated according to Pediatric Oncology Group-protocols (Table <xref ref-type="table" rid="T2">2</xref>). Six out of 16 NBs carried a <italic>MYCN</italic>-amplification initially detected by Southern blot and/or FISH.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Pt</bold></td><td align="left"><bold>Age</bold><sup>a</sup></td><td align="left"><bold>Sex</bold></td><td align="left"><bold>Diagnosis</bold></td><td align="left"><bold>Localization</bold></td><td align="left"><bold>Histology</bold><sup>b</sup></td><td align="left"><bold>MYCN</bold><sup>c</sup></td><td align="left"><bold>Treatment and follow-up</bold></td><td align="left"><bold>Status</bold></td></tr></thead><tbody><tr><td align="left"><italic>1</italic>.</td><td align="left">3 mnts</td><td align="left">F</td><td align="left">NB IV S</td><td align="left">Adnex and liver metastasis</td><td align="left">UD</td><td align="left">No</td><td align="left">05/'01 surgery + chemo</td><td align="left">Alive</td></tr><tr><td align="left"><italic>2</italic>.</td><td align="left">3 yrs</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Supraclavicular and BM metastases</td><td align="left">PD</td><td align="left">No</td><td align="left">02/'03 surgery + chemo<break/>07/'03 chemo, SCR + RT</td><td align="left">Alive</td></tr><tr><td align="left"><italic>3</italic>.</td><td align="left">4 mnts</td><td align="left">M</td><td align="left">NB II</td><td align="left">Pos. lymphnodes with unknown primary tumor</td><td align="left">PD</td><td align="left">No</td><td align="left">01/'03 surgery + chemo</td><td align="left">Alive</td></tr><tr><td align="left"><italic>4</italic>.</td><td align="left">5 mnts</td><td align="left">M</td><td align="left">NB IV S</td><td align="left">Spine and bone/liver metastases</td><td align="left">PD</td><td align="left">No</td><td align="left">01/'01 surgery + chemo</td><td align="left">Alive</td></tr><tr><td align="left"><italic>5</italic>.</td><td align="left">14 mnts</td><td align="left">F</td><td align="left">NB II</td><td align="left">Spine</td><td align="left">PD</td><td align="left">No</td><td align="left">02/'04 surgery + chemo</td><td align="left">Alive</td></tr><tr><td align="left"><italic>6</italic>.</td><td align="left">4 mnts</td><td align="left">F</td><td align="left">NB II</td><td align="left">Adnex</td><td align="left">PD</td><td align="left">No</td><td align="left">07/'01 surgery + chemo</td><td align="left">Alive</td></tr><tr><td align="left"><italic>7</italic>.</td><td align="left">2 yrs</td><td align="left">F</td><td align="left">NB III</td><td align="left">Adnex</td><td align="left">D</td><td align="left">No</td><td align="left">01/'02 chemo + sugery</td><td align="left">Alive</td></tr><tr><td align="left"><italic>8</italic>.</td><td align="left">3 mnts</td><td align="left">M</td><td align="left">NB I</td><td align="left">Adnex</td><td align="left">D</td><td align="left">No</td><td align="left">02/'02 Surgery</td><td align="left">Alive</td></tr><tr><td align="left"><italic>9</italic>.</td><td align="left">2 yrs</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Adnex with bone/BM metastases</td><td align="left">D<sup>d</sup></td><td align="left">No</td><td align="left">12/'03 chemo, SCR + RT<break/>10/'04 relapse treatment</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>10</italic>.</td><td align="left">8 mnts</td><td align="left">F</td><td align="left">NB III</td><td align="left">Spine</td><td align="left">PD</td><td align="left">No</td><td align="left">04/'02 surgery + chemo<break/>12/'02 Surgery spinal relapse</td><td align="left">Alive</td></tr><tr><td align="left"><italic>11</italic>.</td><td align="left">18 mnts</td><td align="left">F</td><td align="left">NB III</td><td align="left">Adnex</td><td align="left">UD<sup>d</sup></td><td align="left">20&#x000d7;</td><td align="left">09/'98 MIBG, chemo + surgery<break/>04/'99 chemo and SCR</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>12</italic>.</td><td align="left">2 yrs</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Adnex and bone metastases</td><td align="left">PD<sup>d</sup></td><td align="left">37 &#x000d7;</td><td align="left">07/'98 surgery, chemo + SCR</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>13</italic>.</td><td align="left">6 yrs</td><td align="left">M</td><td align="left">NB III</td><td align="left">Adnex</td><td align="left">UD</td><td align="left">27 &#x000d7;</td><td align="left">01/'00 surgery, chemo + SCR<break/>11/'03 surgery, chemo + RT</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>14</italic>.</td><td align="left">19 mnts</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Adnex and spine metastasis</td><td align="left">UD</td><td align="left">49 &#x000d7;</td><td align="left">03/'98 MIBG, chemo + surgery</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>15</italic>.</td><td align="left">18 mnts</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Adnex and multiple distal metastases</td><td align="left">n.d.</td><td align="left">139 &#x000d7;</td><td align="left">06/'99 chemo + RT</td><td align="left">d.o.d.</td></tr><tr><td align="left"><italic>16</italic>.</td><td align="left">16 mnts</td><td align="left">M</td><td align="left">NB IV</td><td align="left">Adnex and multiple distal metastases</td><td align="left">UD</td><td align="left">74 &#x000d7;</td><td align="left">01/'97 chemo + surgery</td><td align="left">d.o.d.</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Age at diagnosis</p><p><sup>b</sup>Neuroblastoma differentiation as assessed by pathologist. D = differentiated; PD = poorly differentiated; UD = undifferentiated</p><p><sup>c</sup><italic>MYCN </italic>genomic amplification, as determined with qPCR</p><p><sup>d</sup>Patient has been treated before surgery</p><p>BM = bone marrow; d.o.d. = death of disease; MIBG = meta-iodobenzylguanidine; SCR = stem cell rescue; RT = radiotherapy.</p></table-wrap-foot></table-wrap></sec><sec><title>&#x00394;MYCN expression in the neuroblastoma cell line IMR-32</title><p>Two splice variants have been described for the proto-oncogene <italic>MYCN</italic>, the classical transcript that consists of three exons and a shortened <italic>&#x00394;MYCN </italic>transcript that lacks exon 2. <italic>&#x00394;MYCN </italic>is expressed in several fetal tissues, but its expression has not been reported in NBs. We used primers spanning exon 2 (Figure <xref ref-type="fig" rid="F1">1A</xref> and Table <xref ref-type="table" rid="T1">1</xref>) to visualize by reverse transcriptase PCR whether or not both transcripts are present in MYCN-amplified IMR-32 neuroblastoma cells. Two fragments were identified that corresponded with the expected product lengths of <italic>MYCN </italic>and <italic>&#x00394;MYCN </italic>of respectively 1007 and 100 bp (Figure <xref ref-type="fig" rid="F1">1D</xref>). Sequence analyses on the excised products confirmed that these fragments were <italic>MYCN </italic>and <italic>&#x00394;MYCN</italic>. Absence of additional fragments in the IMR-32 NB cell line suggests that there are no other major MYCN splice variants. To determine whether the &#x00394;MYCN protein is expressed in IMR-32 NB cells, MYCN proteins were visualized with the C-19 antibody that recognizes the c-terminal epitope of both MYCN and &#x00394;MYCN proteins. In the lysate of IMR-32 cells, two protein bands were recognized at approximately 65 and 45 kD, which are the predicted molecular weights of MYCN and &#x00394;MYCN respectively [<xref ref-type="bibr" rid="B18">18</xref>] (Figure <xref ref-type="fig" rid="F2">2A</xref>). For comparison, in a lysate of the melanoma cell line (BLM), which does not carry <italic>MYCN</italic>-amplification, no reactivity could be observed. We conclude from these experiments that the fetal MYCN isoform &#x00394;MYCN is co-expressed with MYCN in IMR-32 cells.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Detection of MYCN and &#x00394;MYCN in IMR-32 cells</bold>. (A) Western blot, visualizing two proteins in the IMR-32 (NB cell line with <italic>MYCN</italic>-amplification) lysate with the C-19 antibody that recognizes the C-terminal epitope of both MYCN and &#x00394;MYCN. In the BLM (melanoma cell line without <italic>MYCN</italic>-amplification) lysate, these proteins were not present. (B) Western blot of IMR-32 whole lysate (1), whole lysate minus precipitate (2) and the precipitate (3) using the C-19 antibody. Arrows indicate the positions of MYCN (65 kDa) and &#x00394;MYCN (45 kDa). The additional band in lane 3 is caused by deposition of Ig-heavy chains (50 kDa). Exposure times are indicated below the blots.</p></caption><graphic xlink:href="1471-2407-9-239-2"/></fig></sec><sec><title>Quantitative analyses of MYCN, &#x00394;MYCN and MYCNOS expression levels in neuroblastomas</title><p>mRNA expression levels of <italic>MYCN</italic>, <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>were measured in 16 human neuroblastoma samples (Table <xref ref-type="table" rid="T2">2</xref>) by QPCR relative to three reference genes: <italic>GUSB, TFRC </italic>and <italic>RNFIII </italic>[<xref ref-type="bibr" rid="B21">21</xref>]. Both <italic>MYCN </italic>and <italic>MYCNOS </italic>were found to be expressed in all 16 NBs. In addition, <italic>&#x00394;MYCN </italic>expression was detected in all NB samples, except for patient 9, who did not carry an amplification of the <italic>MYCN </italic>region. For <italic>MYCN</italic>, it has been demonstrated that the relative expression-levels are significantly higher in NBs with <italic>MYCN</italic>-amplification as compared to non-amplified tumours [<xref ref-type="bibr" rid="B26">26</xref>]. Here, we show that besides <italic>MYCN</italic>, the relative mRNA expression levels of <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>are also significantly increased in NBs with <italic>MYCN</italic>-amplification (p &#x0003c; 0.01; Figure <xref ref-type="fig" rid="F3">3A</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold><italic>MYCN</italic>, <italic>&#x00394;MYCN</italic>, and <italic>MYCNOS </italic>mRNA expression levels in NBs</bold>. (A) Expression levels of <italic>MYCN, &#x00394;MYCN </italic>and <italic>MYCNOS </italic>in <italic>MYCN</italic>-amplified (closed-triangles) compared to non-amplified (open triangles) tumours. (B) Relative expression-levels of <italic>MYCN </italic>(closed triangles), <italic>&#x00394;MYCN </italic>(closed circles) and <italic>MYCNOS </italic>(open circles) correlated to <italic>MYCN-</italic>amplification in NBs. (C) Difference of the <italic>MYCN:MYCNOS</italic>-ratio between NBs with <italic>MYCN</italic>-amplification (closed circles) and NBs without <italic>MYCN</italic>-amplification (open circles). (D) Correlation of the number of <italic>MYCN </italic>copies with <italic>MYCN:MYCNOS </italic>mRNA ratios (closed circles and non-interrupted line) and with <italic>MYCN:MYCN </italic>mRNA ratios (open triangles and dotted line). (E) Correlation between NB stage and <italic>MYCN:MYCNOS</italic>-ratio. (F) Correlation between NB stage and <italic>MYCN: &#x00394;MYCN</italic>-ratio. NB IV-s is a special type of NB characterized by metastatic disease with spontaneous regression and good survival [<xref ref-type="bibr" rid="B31">31</xref>].</p></caption><graphic xlink:href="1471-2407-9-239-3"/></fig><p>Correlation of NB stage with <italic>MYCN:&#x00394;MYCN</italic>-ratio showed that the <italic>MYCN:&#x00394;MYCN</italic>-ratio remains constant and does not change with either <italic>MYCN</italic>-amplification (Figure <xref ref-type="fig" rid="F3">3C</xref>; two-tailed <italic>p</italic>-value = 0.09, calculated with the Students' T-test) or NB stage (Figure <xref ref-type="fig" rid="F3">3F</xref>; two-tailed <italic>p</italic>-value = 0.12, calculated with the Spearman rank correlation). However, there is a significant correlation between the <italic>MYCN:MYCNOS</italic>-ratio and both <italic>MYCN</italic>-amplification (Figure <xref ref-type="fig" rid="F3">3C</xref>; two-tailed <italic>p</italic>-value = 0.025) and NB-stage (Figure <xref ref-type="fig" rid="F3">3E</xref>; two-tailed <italic>p</italic>-value = 0.007). The <italic>MYCNOS:&#x00394;MYCN</italic>-ratio did not significantly change with either <italic>MYCN</italic>-amplification or NB-stage (two-tailed <italic>p</italic>-values = 0.58 and 0.24, respectively; data not shown). These data show that in more advanced NB tumours, mRNA expression of <italic>MYCNO</italic>S increases relative to <italic>MYCN</italic>.</p></sec><sec><title>&#x00394;MYCN and MYCNOS expression relative to level of MYCN-amplification</title><p>To more exactly determine <italic>MYCN </italic>copy number in the tumours that were studied, we performed a genomic quantitative PCR (gQPCR) using genomic primers recognizing five different locations within the <italic>MYCN</italic>-gene (Figure <xref ref-type="fig" rid="F1">1A</xref>; Table <xref ref-type="table" rid="T1">1</xref>). Amplification of these DNA fragments was calculated relative to three reference genes elsewhere on the genome, <italic>CFTR</italic>, <italic>TBX22</italic>, and <italic>SLC16A2</italic>. Among these three reference genes, there were no copy number differences noted in any of the NB samples. All 10 samples with a normal <italic>MYCN</italic>-copy number based on Southern blotting and/or FISH, carried two to four <italic>MYCN </italic>copies as determined by gQPCR. The presence of a <italic>MYCN </italic>duplication in NB cells that lack an overt amplification of <italic>MYCN </italic>is more often found, although the implications for the progression of the NB are still unclear [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. All 6 samples with multiple copies of <italic>MYCN</italic>, as determined by Southern blotting and/or FISH, had in between 20 and 139 <italic>MYCN </italic>gene amplifications (Table <xref ref-type="table" rid="T2">2</xref>), which is within the normal range of gene copy numbers observed in NBs with <italic>MYCN</italic>-amplification [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>We observed that <italic>MYCN </italic>mRNA-expression does not linearly correlate with <italic>MYCN-</italic>amplification, consistent with earlier reports [<xref ref-type="bibr" rid="B26">26</xref>]. In addition, also <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>do not correlate linearly with the number of <italic>MYCN </italic>gene copies (Figure <xref ref-type="fig" rid="F3">3B</xref>). As shown in figure <xref ref-type="fig" rid="F3">3D</xref>, the relative mRNA expression ratio of <italic>MYCN:MYCNOS </italic>decreases with an increasing number of <italic>MYCN </italic>gene copies although this is not significant (non-interrupted line, slope = -0.4; two-tailed <italic>p</italic>-value = 0.18, calculated with the Pearson correlation test). The <italic>MYCN:&#x00394;MYCN </italic>ratio does not change with higher <italic>MYCN </italic>copy numbers (Figure <xref ref-type="fig" rid="F3">3D</xref>; dotted line, slope = -0.1; two-tailed <italic>p</italic>-value = 0.88).</p></sec><sec><title>Overexpression of <italic>MYCNOS </italic>in the NB cell line IMR-32</title><p>The pre-mRNA of <italic>MYCNOS</italic>, which represents the <italic>MYCN </italic>antisense transcript, shows overlap with the first exon of <italic>MYCN</italic>. Therefore <italic>MYCNOS </italic>may potentially modulate <italic>MYCN </italic>mRNA expression levels at the mRNA level via RNA-interference or RNA-editing, or direct <italic>MYCN </italic>splicing by RNA masking [<xref ref-type="bibr" rid="B11">11</xref>]. To test this premise, we transfected IMR-32 NB cells with C1-<italic>GFP </italic>and either the pcDNA3-vector containing <italic>MYCNOS </italic>or an empty vector. IMR-32 cells have relatively high endogenous expression levels of <italic>MYCN</italic>, <italic>MYCNOS </italic>and <italic>&#x00394;MYCN</italic>, which enables quantification of all three mRNA levels. Flow cytometric analyses showed that there was a transfection efficiency of 74% after 72 hours (Figure <xref ref-type="fig" rid="F4">4A</xref>). Although there was a 50-fold increase of <italic>MYCNOS </italic>gene expression in the <italic>MYCNOS</italic>-transfected cell line relative to the empty vector control cell line (Figure <xref ref-type="fig" rid="F4">4B</xref>), expression of endogenous <italic>MYCN </italic>and <italic>&#x00394;MYCN </italic>was not affected either at the mRNA level or at the protein level (Figure <xref ref-type="fig" rid="F4">4B, C</xref>). We conclude that although increased expression of MYCNOS relative to MYCN is correlated with an advanced disease state, RNA-interference or RNA-editing are not the mechanisms by which <italic>MYCNOS </italic>downregulates <italic>MYCN </italic>expression. In addition, the unchanged <italic>MYCN:&#x00394;MYCN </italic>ratio in cells with <italic>MYCNOS </italic>overexpression shows that <italic>MYCNOS </italic>does not affect splicing by RNA-masking.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Overexpression of <italic>MYCNOS </italic>in the NB cell line IMR-32</bold>. (A) Transfection-efficiency was measured by GFP expression as analysed by flow cytometry, 74% of the NB cells expressed GFP 72 hours after transfection. (B) In the <italic>MYCNOS </italic>transfected IMR-32 cells, <italic>MYCNOS </italic>was 50&#x000d7; upregulated compared to not transfected and mock-transfected IMR-32 cells. Endogenous <italic>MYCN </italic>expression was not significantly affected. (C) Western blot showing that MYCN protein expression in <italic>MYCNOS </italic>transfected IMR-32 cells was unaffected. Lane 1 is loaded with lysate from untransfected cells, lane 2 with lysate from cells transfected with the empty vector, and lane 3 with lysate from <italic>MYCNOS </italic>transfected cells.</p></caption><graphic xlink:href="1471-2407-9-239-4"/></fig></sec></sec><sec><title>Discussion</title><p>In this report, we have analysed the expression levels of <italic>MYCN</italic>, <italic>&#x00394;MYCN </italic>and <italic>MYCNOS </italic>in NBs. We find that these three mRNA transcripts are expressed in NBs of all stages, but more highly in NBs with <italic>MYCN</italic>-amplification. The <italic>MYCN:MYCNOS </italic>expression level ratio is significantly decreased in high grade NBs, whereas the <italic>MYCN:&#x00394;MYCN </italic>remains constant in NBs of all stages, which indicates that <italic>MYCN </italic>and <italic>&#x00394;MYCN </italic>are co-regulated. These results suggest that <italic>MYCNOS </italic>might be involved in the regulation of <italic>MYCN </italic>expression levels as has been shown for numerous other antisense transcripts regulating expression of their sense counterparts [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. However, it is important to note that the number of NB samples we investigated is relatively small. Future studies in larger cohorts of patients are needed to further establish a role for <italic>MYCNOS </italic>in the regulation of <italic>MYCN </italic>expression in patients with low-, intermediate- and high-risk NB.</p><p>Natural antisense RNA can inhibit gene expression at the DNA level by transcriptional interference or at the mRNA level by RNA-interference or RNA-editing, or regulate splicing by RNA-masking [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. In RNA-masking, <italic>MYCN-MYCNOS </italic>duplex formation modulates RNA processing by preserving a <italic>MYCN </italic>population that retains intron 1, hence resulting in decreased <italic>&#x00394;MYCN </italic>expression. Krystal <italic>et al</italic>. [<xref ref-type="bibr" rid="B29">29</xref>] showed that RNA-masking can occur, but they found that only approximately 5% of <italic>MYCN </italic>RNA interacts with <italic>MYCNOS </italic>RNA. Our results show that it is unlikely that <italic>MYCNOS </italic>expression has an effect on splicing, since 50-fold overexpression of <italic>MYCNOS </italic>in IMR-32 cells did not change the <italic>MYCN</italic>/<italic>&#x00394;MYCN </italic>expression ratio at the mRNA level. Therefore, inhibition of (<italic>&#x00394;</italic>)<italic>MYCN </italic>expression seems to be the most likely role for <italic>MYCNOS</italic>. There are three mechanisms by which this may be accomplished: transcriptional interference, RNA interference and RNA-editing. Since our results show that overexpression of <italic>MYCNOS </italic>pre-mRNA in NB cell line IMR-32 does not suppress MYCN expression, RNA-interference and RNA-editing do not seem to be the primary inhibitory mechanisms, leaving the possibility that regulation occurs at the DNA level by steric hindrance of the voluminous RNA-polymerase complexes on opposite DNA strands.</p><p>It is not clear how increased expression of <italic>MYCNOS </italic>contributes to the development of NB. Although the increase of <italic>MYCNOS </italic>expression levels is higher than that of <italic>MYCN </italic>in NB with amplification, this difference does not appear to influence the prognosis of patients. In patients with NB but without <italic>MYCN-</italic>amplification, it would be interesting to investigate whether the <italic>MYCN:MYCNOS </italic>ratio is a good prognostic marker. Differences in <italic>MYCNOS </italic>expression levels might explain some of the controversies about <italic>MYCN </italic>expression and prognosis of these patients [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Besides <italic>MYCN </italic>and <italic>MYCNOS</italic>, <italic>&#x00394;MYCN</italic>, which was previously identified as a fetal transcript [<xref ref-type="bibr" rid="B18">18</xref>], is also expressed in NBs. No other <italic>MYCN </italic>isoforms were detected. This suggests that the alternative splice variant that previously has been described by Stanton et al. [<xref ref-type="bibr" rid="B30">30</xref>] and consists of an alternatively spliced exon 1, has little relevance in the progression of NBs. In one tumour, the <italic>&#x00394;MYCN </italic>transcript could not be identified, but this is probably because <italic>&#x00394;MYCN </italic>is low expressed in general and in this tumour <italic>MYCN </italic>was not amplified. The &#x00394;MYCN protein contains a nuclear localization signal, a basic helix-loop-helix, and a leucine-zipper domain, which may serve to dimerize with MYCN or bind to its DNA binding site. &#x00394;MYCN lacks the transactivation domain including the highly conserved Myc 1 and 2 boxes, from which it was speculated that it competes with MYCN and therefore inhibits the active MYCN protein [<xref ref-type="bibr" rid="B18">18</xref>]. However, in all neuroblastoma samples analyzed, the ratio between MYCN and &#x00394;MYCN expression remains constant and does not correlate with <italic>MYCN</italic>-amplification or disease stage, indicating that &#x00394;MYCN induced inhibition of MYCN at the protein level is not of relevance in NB.</p></sec><sec><title>Conclusion</title><p>In conclusion, our results suggest that the expression of the antisense gene <italic>MYCNOS </italic>might be relevant to the progression of NB, potentially by directly inhibiting <italic>MYCN </italic>transcription by transcriptional interference at the DNA level. Analysis of <italic>MYCN:MYCNOS </italic>expression ratios in patients with NB without <italic>MYCN-</italic>amplification and clinical follow-up are necessary to establish the relevance of <italic>MYCNOS </italic>expression to the prognosis of these patients.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JFMJ and APMB designed, performed and analyzed the research and drafted the manuscript. HB and PH conceived of the study. FNL supervised the transfection experiments and helped to draft the manuscript. CAHK performed all pathological characterizations. HB, PMH, GJA and IJMV conducted the study as the principal investigators and contributed to the preparation of the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/239/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Supplemental figure</bold>. Ponceau S stainings of the immunoblot shown in (A) figure <xref ref-type="fig" rid="F2">2a</xref> and (B) 4c</p></caption><media xlink:href="1471-2407-9-239-S1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to thank Dorien Lugtenberg and Jolein Gloerich for technical assistance with the quantitative PCR and the mass spectrometry, respectively. Arjan P.M. de Brouwer was supported by a grant from the Maag-Darm-Lever stichting (grant nr MWO 05-71).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bordow</surname><given-names>SB</given-names></name><name><surname>Norris</surname><given-names>MD</given-names></name><name><surname>Haber</surname><given-names>PS</given-names></name><name><surname>Marshall</surname><given-names>GM</given-names></name><name><surname>Haber</surname><given-names>M</given-names></name></person-group><article-title>Prognostic significance of <italic>MYCN </italic>oncogene expression in childhood neuroblastoma</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>3286</fpage><lpage>3294</lpage><pub-id pub-id-type="pmid">9779703</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthay</surname><given-names>KK</given-names></name></person-group><article-title><italic>MYCN </italic>expression in neuroblastoma: A mixed message?</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>3591</fpage><lpage>3594</lpage><pub-id pub-id-type="pmid">11054431</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>XX</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Kung</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Hicks</surname><given-names>SL</given-names></name><name><surname>Cohn</surname><given-names>SL</given-names></name><name><surname>Cheung</surname><given-names>NK</given-names></name><name><surname>Seeger</surname><given-names>RC</given-names></name><name><surname>Evans</surname><given-names>AE</given-names></name><name><surname>Ikegaki</surname><given-names>N</given-names></name></person-group><article-title>The MYCN enigma: significance of <italic>MYCN </italic>expression in neuroblastoma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>2826</fpage><lpage>2833</lpage><pub-id pub-id-type="pmid">16510605</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0854</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Elsden</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>A</given-names></name><name><surname>Lunec</surname><given-names>J</given-names></name></person-group><article-title>Genes co-amplified with <italic>MYCN </italic>in neuroblastoma: silent passengers or co-determinants of phenotype?</article-title><source>Cancer Lett</source><year>2003</year><volume>197</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">12880964</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(03)00086-7</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>MYCN in neuronal tumours</article-title><source>Cancer Lett</source><year>2004</year><volume>204</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">15013217</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(03)00454-3</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Preter</surname><given-names>K</given-names></name><name><surname>Speleman</surname><given-names>F</given-names></name><name><surname>Combaret</surname><given-names>V</given-names></name><name><surname>Lunec</surname><given-names>J</given-names></name><name><surname>Laureys</surname><given-names>G</given-names></name><name><surname>Eussen</surname><given-names>BH</given-names></name><name><surname>Francotte</surname><given-names>N</given-names></name><name><surname>Board</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>AD</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Van Roy</surname><given-names>N</given-names></name><name><surname>Vandesompele</surname><given-names>J</given-names></name></person-group><article-title>Quantification of <italic>MYCN</italic>, <italic>DDX1</italic>, and <italic>NAG </italic>gene copy number in neuroblastoma using a real-time quantitative PCR assay</article-title><source>Mod Pathol</source><year>2002</year><volume>15</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">11850545</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3880508</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehner</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Campbell</surname><given-names>RD</given-names></name><name><surname>Sanderson</surname><given-names>CM</given-names></name></person-group><article-title>Antisense transcripts in the human genome</article-title><source>Trends Genet</source><year>2002</year><volume>18</volume><fpage>63</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11818131</pub-id><pub-id pub-id-type="doi">10.1016/S0168-9525(02)02598-2</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name></person-group><article-title>Computational discovery of sense-antisense transcription in the human and mouse genomes</article-title><source>Genome Biol</source><year>2002</year><volume>3</volume><fpage>RESEARCH0044</fpage><pub-id pub-id-type="pmid">12225583</pub-id><pub-id pub-id-type="doi">10.1186/gb-2002-3-9-research0044</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>S</given-names></name><name><surname>Crosby</surname><given-names>MA</given-names></name><name><surname>Mungall</surname><given-names>CJ</given-names></name><name><surname>Matthews</surname><given-names>BB</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Hradecky</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Millburn</surname><given-names>GH</given-names></name><name><surname>Prochnik</surname><given-names>SE</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Tupy</surname><given-names>JL</given-names></name><name><surname>Whitfied</surname><given-names>EJ</given-names></name><name><surname>Bayraktaroglu</surname><given-names>L</given-names></name><name><surname>Berman</surname><given-names>BP</given-names></name><name><surname>Bettencourt</surname><given-names>BR</given-names></name><name><surname>Celniker</surname><given-names>SE</given-names></name><name><surname>de Grey</surname><given-names>AD</given-names></name><name><surname>Drysdale</surname><given-names>RA</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>S</given-names></name><name><surname>Schroeder</surname><given-names>AJ</given-names></name><name><surname>Shu</surname><given-names>SQ</given-names></name><name><surname>Stapleton</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>C</given-names></name><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Gelbart</surname><given-names>WM</given-names></name><name><surname>Rubin</surname><given-names>GM</given-names></name><name><surname>Lewis</surname><given-names>SE</given-names></name></person-group><article-title>Annotation of the Drosophila melanogaster euchromatic genome: a systematic review</article-title><source>Genome Biol</source><year>2002</year><volume>3</volume><fpage>RESEARCH0083</fpage><pub-id pub-id-type="pmid">12537572</pub-id><pub-id pub-id-type="doi">10.1186/gb-2002-3-12-research0083</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yelin</surname><given-names>R</given-names></name><name><surname>Dahary</surname><given-names>D</given-names></name><name><surname>Sorek</surname><given-names>R</given-names></name><name><surname>Levanon</surname><given-names>EY</given-names></name><name><surname>Goldstein</surname><given-names>O</given-names></name><name><surname>Shoshan</surname><given-names>A</given-names></name><name><surname>Diber</surname><given-names>A</given-names></name><name><surname>Biton</surname><given-names>S</given-names></name><name><surname>Tamir</surname><given-names>Y</given-names></name><name><surname>Khosravi</surname><given-names>R</given-names></name><name><surname>Nemzer</surname><given-names>S</given-names></name><name><surname>Pinner</surname><given-names>E</given-names></name><name><surname>Walach</surname><given-names>S</given-names></name><name><surname>Bernstein</surname><given-names>J</given-names></name><name><surname>Savitsky</surname><given-names>K</given-names></name><name><surname>Rotman</surname><given-names>G</given-names></name></person-group><article-title>Widespread occurrence of antisense transcription in the human genome</article-title><source>Nat Biotechnol</source><year>2003</year><volume>21</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">12640466</pub-id><pub-id pub-id-type="doi">10.1038/nbt808</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavorgna</surname><given-names>G</given-names></name><name><surname>Dahary</surname><given-names>D</given-names></name><name><surname>Lehner</surname><given-names>B</given-names></name><name><surname>Sorek</surname><given-names>R</given-names></name><name><surname>Sanderson</surname><given-names>CM</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name></person-group><article-title>In search of antisense</article-title><source>Trends Biochem Sci</source><year>2004</year><volume>29</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15102435</pub-id><pub-id pub-id-type="doi">10.1016/j.tibs.2003.12.002</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makalowska</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Makalowski</surname><given-names>W</given-names></name></person-group><article-title>Overlapping genes in vertebrate genomes</article-title><source>Comput Biol Chem</source><year>2005</year><volume>29</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15680581</pub-id><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2004.12.006</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>BC</given-names></name><name><surname>Krystal</surname><given-names>GW</given-names></name></person-group><article-title>Isolation and characterization of complementary DNA for <italic>N-cym</italic>, a gene encoded by the DNA strand opposite to <italic>N-myc</italic></article-title><source>Cell Growth Differ</source><year>1992</year><volume>3</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">1419902</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thrash-Bingham</surname><given-names>CA</given-names></name><name><surname>Tartof</surname><given-names>KD</given-names></name></person-group><article-title><italic>aHIF </italic>: a natural antisense transcript overexpressed in human renal cancer and during hypoxia</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">9923855</pub-id><pub-id pub-id-type="doi">10.1093/jnci/91.2.143</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baguma-Nibasheka</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>AW</given-names></name><name><surname>Osman</surname><given-names>MS</given-names></name><name><surname>Geldenhuys</surname><given-names>L</given-names></name><name><surname>Casson</surname><given-names>AG</given-names></name><name><surname>Too</surname><given-names>CK</given-names></name><name><surname>Murphy</surname><given-names>PR</given-names></name></person-group><article-title>Coexpression and regulation of the <italic>FGF-2 </italic>and <italic>FGF </italic>antisense genes in leukemic cells</article-title><source>Leuk Res</source><year>2005</year><volume>29</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">15725477</pub-id><pub-id pub-id-type="doi">10.1016/j.leukres.2004.09.006</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>F</given-names></name><name><surname>Vache</surname><given-names>C</given-names></name><name><surname>Clottes</surname><given-names>E</given-names></name></person-group><article-title>Natural antisense transcripts of <italic>hypoxia-inducible factor 1alpha </italic>are detected in different normal and tumour human tissues</article-title><source>Gene</source><year>2002</year><volume>299</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">12459261</pub-id><pub-id pub-id-type="doi">10.1016/S0378-1119(02)01049-1</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cayre</surname><given-names>A</given-names></name><name><surname>Rossignol</surname><given-names>F</given-names></name><name><surname>Clottes</surname><given-names>E</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name></person-group><article-title><italic>aHIF </italic>but not <italic>HIF-1alpha </italic>transcript is a poor prognostic marker in human breast cancer</article-title><source>Breast Cancer Res</source><year>2003</year><volume>5</volume><fpage>R223</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">14580258</pub-id><pub-id pub-id-type="doi">10.1186/bcr652</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Bokhoven</surname><given-names>H</given-names></name><name><surname>Celli</surname><given-names>J</given-names></name><name><surname>van Reeuwijk</surname><given-names>J</given-names></name><name><surname>Rinne</surname><given-names>T</given-names></name><name><surname>Glaudemans</surname><given-names>B</given-names></name><name><surname>van Beusekom</surname><given-names>E</given-names></name><name><surname>Rieu</surname><given-names>P</given-names></name><name><surname>Newbury-Ecob</surname><given-names>RA</given-names></name><name><surname>Chiang</surname><given-names>C</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name></person-group><article-title><italic>MYCN </italic>haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>465</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">15821734</pub-id><pub-id pub-id-type="doi">10.1038/ng1546</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozen</surname><given-names>S</given-names></name><name><surname>Skaletsky</surname><given-names>H</given-names></name></person-group><article-title>Primer3 on the WWW for general users and for biologist programmers</article-title><source>Methods Mol Biol</source><year>2000</year><volume>132</volume><fpage>365</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">10547847</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcelis</surname><given-names>CL</given-names></name><name><surname>Hol</surname><given-names>FA</given-names></name><name><surname>Graham</surname><given-names>GE</given-names></name><name><surname>Rieu</surname><given-names>PN</given-names></name><name><surname>Kellermayer</surname><given-names>R</given-names></name><name><surname>Meijer</surname><given-names>RP</given-names></name><name><surname>Lugtenberg</surname><given-names>D</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name><name><surname>van Bokhoven</surname><given-names>H</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>de Brouwer</surname><given-names>APM</given-names></name></person-group><article-title>Genotype-phenotype correlations in <italic>MYCN</italic>-related Feingold syndrome</article-title><source>Hum Mutat</source><year>2008</year><volume>29</volume><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">18470948</pub-id><pub-id pub-id-type="doi">10.1002/humu.20750</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Brouwer</surname><given-names>AP</given-names></name><name><surname>van Bokhoven</surname><given-names>H</given-names></name><name><surname>Kremer</surname><given-names>H</given-names></name></person-group><article-title>Comparison of 12 reference genes for normalization of gene expression levels in Epstein-Barr virus-transformed lymphoblastoid cell lines and fibroblasts</article-title><source>Mol Diagn Ther</source><year>2006</year><volume>10</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16771605</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">11846609</pub-id><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfaffl</surname><given-names>MW</given-names></name></person-group><article-title>A new mathematical model for relative quantification in real-time RT-PCR</article-title><source>Nucleic Acids Res</source><year>2001</year><volume>29</volume><fpage>e45</fpage><pub-id pub-id-type="pmid">11328886</pub-id><pub-id pub-id-type="doi">10.1093/nar/29.9.e45</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoebeeck</surname><given-names>J</given-names></name><name><surname>Speleman</surname><given-names>F</given-names></name><name><surname>Vandesompele</surname><given-names>J</given-names></name></person-group><article-title>Real-time quantitative PCR as an alternative to Southern blot or fluorescence in situ hybridization for detection of gene copy number changes</article-title><source>Methods Molecular Biol</source><year>2007</year><volume>353</volume><fpage>205</fpage><lpage>226</lpage></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Umehara</surname><given-names>S</given-names></name><name><surname>Monobe</surname><given-names>Y</given-names></name><name><surname>Hachitanda</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>A</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Gerbing</surname><given-names>RB</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Lukens</surname><given-names>JN</given-names></name><name><surname>Matthay</surname><given-names>KK</given-names></name></person-group><article-title>International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>2451</fpage><lpage>2461</lpage><pub-id pub-id-type="pmid">11745303</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(20011101)92:9&#x0003c;2451::AID-CNCR1595&#x0003e;3.0.CO;2-S</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Tajiri</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>S</given-names></name><name><surname>Shono</surname><given-names>K</given-names></name><name><surname>Ihara</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Suita</surname><given-names>S</given-names></name></person-group><article-title>Clinical significance of a highly sensitive analysis for gene dosage and the expression level of <italic>MYCN </italic>in neuroblastoma</article-title><source>J Pediatr Surg</source><year>2004</year><volume>39</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">14694373</pub-id><pub-id pub-id-type="doi">10.1016/j.jpedsurg.2003.09.015</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corvi</surname><given-names>R</given-names></name><name><surname>Savelyeva</surname><given-names>L</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Duplication of <italic>N-MYC </italic>at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>3471</fpage><lpage>3474</lpage><pub-id pub-id-type="pmid">7627947</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Ellison</surname><given-names>J</given-names></name><name><surname>Busch</surname><given-names>M</given-names></name><name><surname>Rosenau</surname><given-names>W</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>Enhanced expression of the human gene <italic>N-myc </italic>consequent to amplification of DNA may contribute to malignant progression of neuroblastoma</article-title><source>Proc Natl Acad Sci USA</source><year>1984</year><volume>81</volume><fpage>4940</fpage><lpage>4944</lpage><pub-id pub-id-type="pmid">6589638</pub-id><pub-id pub-id-type="doi">10.1073/pnas.81.15.4940</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krystal</surname><given-names>GW</given-names></name><name><surname>Armstrong</surname><given-names>BC</given-names></name><name><surname>Battey</surname><given-names>JF</given-names></name></person-group><article-title><italic>N-myc </italic>mRNA forms an RNA-RNA duplex with endogenous antisense transcripts</article-title><source>Mol Cell Biol</source><year>1990</year><volume>10</volume><fpage>4180</fpage><lpage>4191</lpage><pub-id pub-id-type="pmid">1695323</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanton</surname><given-names>LW</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>Alternative processing of RNA transcribed from NMYC</article-title><source>Mol Cell Biol</source><year>1987</year><volume>7</volume><fpage>4266</fpage><lpage>4272</lpage><pub-id pub-id-type="pmid">3437890</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nickerson</surname><given-names>HJ</given-names></name><name><surname>Matthay</surname><given-names>KK</given-names></name><name><surname>Seeger</surname><given-names>RC</given-names></name><name><surname>Brodeur</surname><given-names>GM</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Perez</surname><given-names>C</given-names></name><name><surname>Atkinson</surname><given-names>JB</given-names></name><name><surname>Selch</surname><given-names>M</given-names></name><name><surname>Gerbing</surname><given-names>RB</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Lukens</surname><given-names>J</given-names></name></person-group><article-title>Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">10653863</pub-id></citation></ref></ref-list></back></article> 